Portal Login:
  • Clients
  • Providers
  • Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
    Portal Login:
  • Clients
  • Providers
  • About MCN
  • Careers
  • MCNTalk
  • Contact Us

MCN | Medical Consultants Network

The Power of a Second Look

  • Services
    • Independent Medical Examinations
    • Medical Peer Reviews
    • Bill Review Services
    • Utilization Reviews
  • Expertise
    • Short and Long-Term Disability
    • Workers’ Compensation
    • Auto/PIP/Casualty/Liability
    • Independent Review Organization Services
  • For Clients
  • For Providers
  • Your Exam
    • About Your Exam
    • About Your External Review
    • Contact & Scheduling
  • Schedule Now
  • About MCN
  • MCNTalk
  • Careers
  • Contact Us

MCNTalk
News, Insights & Opinions

Home / MCNTalk / The (shocking) cost of asthma

October 14, 2013

The (shocking) cost of asthma

What consumer items in the US are priced at such a massive differential to Europe and elsewhere besides medications? Lobbying pays nicely it would appear. This is not just a problem for those with asthma or other illnesses requiring increasingly costly drugs. This is a problem for every patient, every insured, every taxpayer, and every employer who pays for insurance. This is of course due to the risk sharing inherent in any insurance system, where the healthier pay for the sicker. This means higher premiums, copays, deductibles, lower business profits, and lower pay due to business costs being shifted to higher benefits.

It is also a problem for caring physicians who are faced with the dilemma of helping their patients who may have to pay all or some medication costs out of pocket due to no, or limited, insurance coverage.

We are currently in a government shut-down, in part due to a small number of politicians who want to preserve this status quo – or at least it appears they do. The rhetoric attacks reform and change. The corollary of these attacks is that we leave things largely alone, including these windfall abuses of regulation.

In the free market that most believe in theoretically, safe drugs like those sold in Europe would be available in the US, unimpeded by protective and restrictive regulations that protect certain companies and products from competition. We currently have a system that is a far cry from free, rational, or equitable.

Innovation is not always comfortable. Change when it takes place will be disruptive, and it will be resisted. But it is necessary.

Share this:

  • Twitter
  • Email
  • More
  • Facebook
  • Reddit
  • Print

Tagged: Cost Containment, Government Policy, Health Policy, Legal Issues, Regulatory Issues Leave a Comment

Previous Post
Next Post

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

4 + 16 =

Primary Sidebar

Recent Posts

  • The Quality Divide: What Makes a Quality IME Physician?
  • The Quality Divide: Is Your Vendor Driving IME Excellence?
  • The Quality Divide: When and How to Request an IME?
  • April Clinic Calendars Are Available
  • MCN’s Client Portal Login Page is Changing

Archives

Footer


  • Twitter
  • LinkedIn

Quick Links

  • Services
  • Expertise
  • About MCN
  • Careers

Division Headquarters

MCN
1200 5th Ave., Ste. 650
Seattle, WA 98101

See all offices

Email Us

General Inquiries: info@mcn.com
Sales & Marketing: marketing@mcn.com

Call Us

206.343.6100
800.248.6269

© Copyright 2022 Mitchell International, Inc. All Rights Reserved.

  • Privacy Policy
  • Sitemap
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.